In order to improve the mechanism of technology transfer, the National Center of Technology Innovation for Biopharmaceuticals and BioBAY recently jointly organized the Biopharmaceutical "Industry-University-Research-Hospital" integration development forum, and launched the clinical cooperation ceremony. At the ceremony, five authoritative medical institutions and leading innovative medical enterprises in Suzhou signed a strategic cooperation framework agreement. As one of the representative enterprises of hospital-enterprise cooperation in Suzhou Industrial Park, RainMed Medical was invited to participate in the launch ceremony. Mr. Kangjian Liu, Vice President and Secretary of the Board of RainMed Medical, represented the company to sign the strategic cooperation agreement with Professor Yafeng Zhou, Vice President of Dushu Lake Hospital Affiliated to Soochow University, a key comprehensive hospital in Suzhou.

Clinical research has always been an indispensable key factor in the medical progress of innovation industry in China. In order to solve the pain points of the clinical resource docking needs of biopharmaceutical enterprises, support the integration and innovative development of health and biopharmaceutical industries, and create a new situation of high-quality development of hospital-enterprise cooperation, Suzhou has successively introduced relevant policies and established the Suzhou Clinical Research Service Platform to support clinical resources for research and development and industrial development services, promote the coordinated development of basic medical research and clinical treatment, accelerate the clinical transformation of new diagnostic and therapeutic technologies, and improve the research and development speed of biopharmaceutical enterprises. This signing cooperation will help RainMed Medical better focus on clinical research, develop more innovative diagnostic and therapeutic products with clinical value and practicality.

As a national high-tech enterprise, RainMed Medical focuses on the precise diagnosis and treatment of vascular diseases, attaches great importance to the cultivation of scientific research talents, focuses on independent innovation and research, continuously promotes the transformation of advanced scientific research results in combination with medical treatment, and innovatively launches a series of revolutionary precise diagnosis and treatment products for vascular diseases. RainMed also took the lead in differentiating the layout of integrated diagnosis and treatment vascular intervention surgical robots, known as the first domestic vascular intervention surgical robots, leading the vigorous development of China's pan-vascular intervention surgical robot. Currently, the company's commercialized functional diagnostic products have been widely praised and applied by experts and scholars around the world, and the high-quality diagnostic and treatment services provided by the products cover more than 1,100 hospitals in 30 provinces, municipalities, and autonomous regions in China, as well as more than 10 overseas countries and regions.

Policy support is a powerful support for technological innovation. RainMed Medical has an outstanding talent team and advanced research and development production level. The promotion of hospital-enterprise cooperation by governments at all levels will help the company grasp clinical demands and scientific research innovation more accurately. In the future, RainMed Medical will continue to deepen hospital-enterprise cooperation, closely combine clinical demands, provide cutting-edge diagnostic methods for vascular diseases, and contribute corporate wisdom to promote the Healthy China.